GSK/THRX report phase-3 data for “son of Advair” combination product for COPD and asthma: http://finance.yahoo.com/news/GSK-and-Theravance-Announce-iw-1854321990.html?x=0&.v=1 I may comment further after listening to the CC. In the meantime, anyone who has a handle on this program should please chime in!